Institutional Ownership
Lexeo Therapeutics Inc
CUSIP 52886X107COMLXEOQ1 2026
13D / 13G Filings
52
Schedule 13D/13G on record
Beneficial Filers
22
Distinct reporting persons
Largest Stake
13.7%
Max % of class reported
Institutional Holders
133
13F filers (latest quarter)
Beneficial Owners — Schedule 13D / 13G
52 filings · latest Feb 17, 2026
| # | Filed | Reporting Person | Form | % of Class | Shares | Filing |
|---|---|---|---|---|---|---|
| 1 | Feb 17, 2026 | Balyasny Asset Management L.P. | 13G/A | 9.9% | 7.22M | SEC |
| 2 | Feb 17, 2026 | Citadel Advisors LLC | 13G/A | 7.4% | 5.50M | SEC |
| 3 | Feb 17, 2026 | Paradigm Biocapital Advisors LP | 13G/A | 6.5% | 9.23B | SEC |
| 4 | Feb 13, 2026 | Frazier Life Sciences Public Fund, L.P. | 13G/A | 5.1% | 3.70M | SEC |
| 5 | Jan 30, 2026 | The Vanguard Group | 13G | 5.3% | 3.89M | SEC |
| 6 | Jan 29, 2026 | Affinity Asset Advisors, LLC | 13G/A | 7.1% | 5.22M | SEC |
| 7 | Jan 21, 2026 | Blackrock, Inc. | 13G | 6.7% | 4.89M | SEC |
| 8 | Dec 8, 2025 | Janus Henderson Group PLC | 13G/A | 10.0% | 7.29M | SEC |
| 9 | Nov 20, 2025 | Paradigm Biocapital Advisors LP | 13G | 5.0% | 92.13M | SEC |
| 10 | Nov 14, 2025 | Janus Henderson Group PLC | 13G/A | 11.3% | 6.11M | SEC |
42 more beneficial-ownership filings on Premium
See the full Schedule 13D/13G history for Lexeo Therapeutics Inc.
Unlock full historyTop Institutional Holders (13F)
Largest reported positions · latest quarter
| # | Fund | Shares | Value |
|---|---|---|---|
| 1 | Paradigm Biocapital Advisors LP | 6.18M | $35.50M |
| 2 | Blackrock, Inc. | 5.11M | $29.34M |
| 3 | Affinity Asset Advisors, LLC | 5.05M | $28.99M |
| 4 | Ra Capital Management, L.P. | 5.00M | $28.70M |
| 5 | Janus Henderson Group PLC | 4.98M | $28.51M |
| 6 | Vestal Point Capital, LP | 4.47M | $25.69M |
| 7 | Frazier Life Sciences Management, L.P. | 4.42M | $25.40M |
| 8 | Citadel Advisors LLC | 3.83M | $22.01M |
| 9 | Orbimed Advisors LLC | 3.60M | $20.68M |
| 10 | State Street Corp | 3.57M | $20.48M |